Caribou Biosciences Inc
CRBU1.570USD
+0.090+6.08%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
146.74MCap. mercado
PérdidaP/E TTM
Más Datos de Caribou Biosciences Inc Compañía
Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company engaged in developing transformative therapies for patients with devastating diseases. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform to offer broad access and rapid availability of treatments for patients with hematologic malignancies and autoimmune diseases. Its genome-editing platform, including its novel chRDNA technology, enables more precise genome editing of allogeneic cell therapies. It is advancing its pipeline of allogeneic CAR-T cell therapies with clinical development programs targeting the treatment of hematologic malignancies and autoimmune diseases.
Información de Caribou Biosciences Inc
Símbolo de cotizaciónCRBU
Nombre de la empresaCaribou Biosciences Inc
Fecha de salida a bolsaJul 23, 2021
Director ejecutivoHaurwitz (Rachel E)
Número de empleados147
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 23
Dirección2929 7Th Street, Ste 120
CiudadBERKELEY
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94710
Teléfono15109826030
Sitio Webhttps://www.cariboubio.com/
Símbolo de cotizaciónCRBU
Fecha de salida a bolsaJul 23, 2021
Director ejecutivoHaurwitz (Rachel E)
Ejecutivos de Caribou Biosciences Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Barbara G. McClung, J.D.
Ms. Barbara G. McClung, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
381.25K
-29250.00%
Mr. Sriram (Sri) Ryali
Mr. Sriram (Sri) Ryali
Chief Financial Officer
Chief Financial Officer
17.36K
+17360.00%
Mr. Tim Kelly
Mr. Tim Kelly
Chief Technology Officer
Chief Technology Officer
--
--
Dr. Tina Albertson, M.D., Ph.D.
Dr. Tina Albertson, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Rachel E. Haurwitz, Ph.D.
Dr. Rachel E. Haurwitz, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
--
--
Dr. Nancy C. Whiting, Pharm.D.
Dr. Nancy C. Whiting, Pharm.D.
Independent Director
Independent Director
--
--
Ms. Ran Zheng
Ms. Ran Zheng
Independent Director
Independent Director
--
--
Dr. Dara Richardson-Heron, M.D.
Dr. Dara Richardson-Heron, M.D.
Independent Director
Independent Director
--
--
Ms. Ruhi A. Khan
Ms. Ruhi A. Khan
Chief Business Officer
Chief Business Officer
--
--
Dr. Scott N. Braunstein, M.D.
Dr. Scott N. Braunstein, M.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Barbara G. McClung, J.D.
Ms. Barbara G. McClung, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
381.25K
-29250.00%
Mr. Sriram (Sri) Ryali
Mr. Sriram (Sri) Ryali
Chief Financial Officer
Chief Financial Officer
17.36K
+17360.00%
Mr. Tim Kelly
Mr. Tim Kelly
Chief Technology Officer
Chief Technology Officer
--
--
Dr. Tina Albertson, M.D., Ph.D.
Dr. Tina Albertson, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Rachel E. Haurwitz, Ph.D.
Dr. Rachel E. Haurwitz, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
--
--
Dr. Nancy C. Whiting, Pharm.D.
Dr. Nancy C. Whiting, Pharm.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
Divisa: USDActualizado: mar., 6 de ene
Divisa: USDActualizado: mar., 6 de ene
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
La empresa aún no ha revelado los datos relevantes.
Por regiónUSD
Nombre
Ganancia
Proporción
United States
1.82M
82.85%
Rest of world
377.00K
17.15%
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: sáb., 31 de ene
Actualizado: sáb., 31 de ene
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Pfizer Inc
5.02%
The Vanguard Group, Inc.
4.61%
Haurwitz (Rachel E. Ph.D.)
3.68%
Millennium Management LLC
3.44%
Kynam Capital Management LP
3.28%
Otro
79.97%
Accionistas
Accionistas
Proporción
Pfizer Inc
5.02%
The Vanguard Group, Inc.
4.61%
Haurwitz (Rachel E. Ph.D.)
3.68%
Millennium Management LLC
3.44%
Kynam Capital Management LP
3.28%
Otro
79.97%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
17.01%
Hedge Fund
13.83%
Investment Advisor/Hedge Fund
5.57%
Corporation
5.02%
Individual Investor
4.72%
Research Firm
2.40%
Private Equity
0.83%
Venture Capital
0.47%
Bank and Trust
0.09%
Otro
50.06%
Participación institucional
Actualizado: lun., 8 de dic
Actualizado: lun., 8 de dic
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
336
36.52M
71.18%
+8.50K
2025Q3
343
36.51M
75.34%
-3.42M
2025Q2
344
39.93M
84.21%
-9.67M
2025Q1
343
49.60M
89.75%
-33.86M
2024Q4
341
57.02M
91.20%
-746.04K
2024Q3
336
56.25M
89.23%
-1.72M
2024Q2
332
57.28M
88.69%
-12.92M
2024Q1
319
69.74M
90.55%
-12.04M
2023Q4
311
71.96M
89.62%
-1.70M
2023Q3
307
73.59M
61.71%
+24.32M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Pfizer Inc
4.69M
5.02%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
4.23M
4.52%
+137.06K
+3.35%
Sep 30, 2025
Haurwitz (Rachel E. Ph.D.)
3.44M
3.68%
-87.08K
-2.47%
Apr 22, 2025
Millennium Management LLC
3.22M
3.44%
+1.67M
+107.44%
Sep 30, 2025
Kynam Capital Management LP
3.07M
3.28%
--
--
Sep 30, 2025
Two Sigma Investments, LP
2.01M
2.15%
-365.33K
-15.37%
Sep 30, 2025
ACATIS Investment Kapitalverwaltungsgesellschaft GmbH
2.00M
2.14%
--
--
Sep 30, 2025
SELECTRA Management Company S.A.
1.65M
1.77%
+120.00K
+7.84%
Nov 30, 2025
BlackRock Institutional Trust Company, N.A.
1.45M
1.55%
-380.57K
-20.78%
Sep 30, 2025
abrdn Inc.
1.39M
1.49%
+491.33K
+54.74%
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
AXS Green Alpha ETF
1.24%
WisdomTree BioRevolution Fund
0.52%
Avantis US Small Cap Equity ETF
0.01%
Schwab U.S. Small-Cap ETF
0.01%
DFA Dimensional US Core Equity Market ETF
0%
Global X Genomics & Biotechnology ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
ProShares Hedge Replication ETF
0%
Pacer WealthShield ETF
0%
ProShares UltraPro Russell2000
0%
Ver más
AXS Green Alpha ETF
Proporción1.24%
WisdomTree BioRevolution Fund
Proporción0.52%
Avantis US Small Cap Equity ETF
Proporción0.01%
Schwab U.S. Small-Cap ETF
Proporción0.01%
DFA Dimensional US Core Equity Market ETF
Proporción0%
Global X Genomics & Biotechnology ETF
Proporción0%
ProShares Ultra Nasdaq Biotechnology
Proporción0%
ProShares Hedge Replication ETF
Proporción0%
Pacer WealthShield ETF
Proporción0%
ProShares UltraPro Russell2000
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
